RxDoctor Payments Data

Jennifer McCarthy

Acute Care · Newark, NJNPI 1598952343

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,000 of the $16,145 with a category attached, or 74.3%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 79.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $4,995 and has fallen 89.1% since, to $543 in 2025. Among acute care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,145in general payments, 2019–2025

Across 101 payments — averaging $159.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13K
  • Boston Scientific$760
  • Abbott$736
  • Cvrx, Inc.$432
  • Medtronic$420
  • Atricure, Inc.$265
  • plus $770 from 13 others

What the payments were for

  • Consulting fees$1,1207%
  • Speaking & faculty fees$12,00074%
  • Travel & lodging$620%
  • Food & beverage$2,88418%
  • Education$790%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,145 in reported general payments places this provider in the 95th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$20,625
Medicare patients
82
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$75,051
XareltoRivaroxaban13$9,304
EntrestoSacubitril/Valsartan11$8,943
Amiodarone Hcl78$802
Carvedilol43$415
Metoprolol Succinate36$354
Potassium Chloride17$167
Metoprolol Tartrate24$91
Furosemide14$47
Warfarin Sodium12$42
Atorvastatin Calcium16$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$75,051106 claims
Johnson & JohnsonXarelto$56$9,30413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 656 acute care providers in New Jersey.

Other acute care in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →